

# 2015 Pathology 2.0 group of ESTP Webinars

Tissue section-based investigative technologies

With the objective of continuous pathology education, ESTP Pathology 2.0 group invites you to a series of 4 webinars on Advanced Pathology Technologies during this year. The second and third webinars will focus on digital image analysis of immunohistochemistry and *in situ* hybridization and it's uses to quantify biomarker expression and utilization as a multiplexing tool.

## ***Webinar 3. Digital Image Analysis and Multiplexing of Biomarkers – Part 2***

Speaker: **Helen Angell**, BSc, PhD

Senior Scientist, Molecular Pathology, Translational Science, Oncology iMed, AstraZeneca.

Moderator: **Famke Aeffner**, DVM, PhD, DACVP

Associate Director of Pathology; Flagship Biosciences Inc.

Date: **Wednesday, 5<sup>th</sup> August 2015 at 2 p.m. CET**

To register, please visit the meetings section of the [ESTP website](http://www.eurotoxpath.org).



## Objectives:

- This is the second of a two-part series of webinars addressing image analysis and multiplexing of IHC and/or ISH labelling in tissue sections.
- The 45 minute webinar will cover examples of working with different digital image analysis platforms and their utility to quantify biomarker expression in IHC and IF stained sections. Specific aspects that will be covered include:
  - Platform comparison and examples (Aperio, HALO, Definiens, Perkin Elmer)
  - IHC and IF multiplexing
  - Future perspectives: getting the most from your tissue (Nanostring, CyTOF)
- The 15 minute Q&A session will allow the participants to ask questions directly to the speaker and the moderator

## Who should attend?

- Pathologists, residents and scientists working with FFPE.
- Little prior knowledge of digital image analysis is required.



## Short Bio of Speaker:

**Famke Aeffner, DVM, PhD, DACVP**

***Associate Director of Pathology, Flagship Biosciences Inc.***

Dr. Aeffner graduated from the combined veterinary anatomic pathology and PhD program at The Ohio State University. Her special expertise is in the field of digital quantitative image analysis of human and laboratory animal histology specimens, infectious diseases, oncology, medical devices and animal models of human disease. Dr. Aeffner has extensive experience in biomarker assay development and interpretation of chromogenic and fluorescent immunohistochemistry, involving evaluation of tissues from discovery and efficacy studies and in retrospective analysis of clinical trial tissues.



**Helen Angell, B.Sc., Ph.D.**

***Senior Scientist, Molecular Pathology, Oncology iMed, AstraZeneca***

Dr. Helen K. Angell received a first class B.Sc. in Biochemistry from the University of Manchester, with industrial placement at MedImmune, Cambridge, and was awarded the Bioscience Horizons Young Scientist Award, 2008. She received a Ph.D. entitled 'Immune Modulation of the Tumour Microenvironment' from the University of Nottingham School of Pharmacy, funded by AstraZeneca and EPSRC. The project spanned several interdisciplinary projects, culminating in receipt of the AstraZeneca iMed Scientific Innovations Award. Dr. Angell then took a postdoctoral role with Dr. Jérôme Galon in the Laboratory of Integrative Immunology at the Cordeliers Research Centre, Paris. Here she contributed to the development and implementation of the 'Immunoscore'. Her main research focus was the characterisation and phenotyping of immune subpopulations, cytokines, chemokines and tumour alteration, associated with CRC progression, recurrence and metastasis. In January 2014 Dr. Angell joined AstraZeneca's Oncology iMed team as a senior scientist within the Molecular Pathology Group, Translational Science.

